BioSig to Highlight PURE EP™ System at the Benzinga Global Small Cap Conference
03 déc. 2020 11h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Dec. 03, 2020 (GLOBE NEWSWIRE) -- The company's PURE EP™ System is currently installed in six medical centers across the countryEvaluation installations are growing and provide a...
BioSig’s PURE EP System to Support Live Patient Cases during EPLive 2020
30 nov. 2020 11h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Nov. 30, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing...
BioSig to Host Business Update Conference Call on November 18, 2020
12 nov. 2020 14h11 HE
|
BioSig Technologies, Inc.
Westport, CT, Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal...
BioSig Announces Completion of PURE EP™ System Installation at New Medical Center
29 oct. 2020 14h05 HE
|
BioSig Technologies, Inc.
Westport, CT, Oct. 29, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal...
BioSig Issues October 2020 Shareholder Update Letter
28 oct. 2020 10h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Company’s PURE EP™ System’s data-driven commercialization is gaining acceptance through new evaluative installations at medical centers of...
SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform
06 oct. 2020 09h00 HE
|
SetPoint Medical
VALENCIA, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for...
SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19
30 sept. 2020 09h27 HE
|
BioSig Technologies, Inc.
Westport, CT, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Sorrento to initiate testing with a selection of its agents in combination with ViralClear’s anti-viral compound for possible synergistic anti-viral...
ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution
22 sept. 2020 10h55 HE
|
BioSig Technologies, Inc.
Westport, CT, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Size of ongoing Phase 2 trial of merimepodib in combination with remdesivir increased from 40 to 80 subjects, with focus on hospitalized patients...
Reminder: ViralClear to Host Conference Call and Webcast on September 22, 2020 to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19
21 sept. 2020 11h01 HE
|
BioSig Technologies, Inc.
Westport, CT, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Merimepodib in Combination with Remdesivir in Hospitalized Adults with COVID-19 Who...
BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology’s ‘ESC Congress 2020’
15 sept. 2020 10h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Sept. 15, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal...